This content is machine translated New study on combined immunotherapy in melanoma Combination of nivolumab and ipilimumab is superior to monotherapy Melanomas account for less than 5% of all skin cancers, but they claim the most lives. How to optimize the therapy? The CheckMate-069 trial, published in the New England Journal…
